"POLAR-izing" Findings From Trials of Neuroprotection for Oxaliplatin Neuropathy
- PMID: 36308449
- PMCID: PMC9673911
- DOI: 10.1093/jncics/pkac076
"POLAR-izing" Findings From Trials of Neuroprotection for Oxaliplatin Neuropathy
Comment on
-
Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M).JNCI Cancer Spectr. 2022 Nov 1;6(6):pkac075. doi: 10.1093/jncics/pkac075. JNCI Cancer Spectr. 2022. PMID: 36308441 Free PMC article. Clinical Trial.
References
-
- Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F.. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006;33(1):15-49. - PubMed
-
- Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV.. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31(21):2699-2707. - PubMed
-
- Beijers AJM, Mols F, Vreugdenhil G.. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22(7):1999-2007. - PubMed
-
- Teng C, Cohen J, Egger S, Blinman PL, Vardy JL.. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer. Support Care Cancer. 2022;30(1):33-47. - PubMed
-
- Teng C, Blinman PL, Venkatesha V, Vardy JL.. Patterns of patient-reported chemotherapy-induced peripheral neuropathy in colorectal cancer survivors. J Natl Compr Canc Netw. 2022. In press (accepted 1 July 2022). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical